02-14-05 16:55 From-HUNTON & WILLIAMS ÷ T-587 P.01 F-524

## CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that on Monday February 14, 2005, the following correspondence pertaining to U.S. Patent Application Number 09/546,573, is being transmitted to Examiner S. L. Rawlings, Ph.D. at the U.S. Patent and Trademark Office to facsimile number (703) 872-9306:

- (1) Copy of:
  - (a) Supplemental Amendment Under 37 C.F.R. 1.111

RECEIVED
CENTRAL FAX CENTER

FEB 1 4 2005

February 14, 2005	_
Date	Mali Sa
Stacey A. Chandler Typed or printed name of person signing Certificate	Signature

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

PATENT ATTORNEY DOCKET NO. 59866,000002

IN THE UNITED STATES	PATEN	T AND TRADEMARK OFFICE RECEIVED
In re Patent Application of:	)	CENTRAL FAX CENTER
M. N. Holten-Andersen et al.	)	Confirmation No.: 3408 FEB 1 4 2005
Serial No.: 09/546,573	ý	Art Unit: 1642
Filed: April 10, 2000	)	Examiner: S. L. Rawlings, Ph.D.

For: TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES

TYPE-1 (TIMP-1) AS A CANCER MARKER

## SUPPLEMENTAL AMENDMENT LINDER 37 C.F.R. St. 111

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## I. Introductory Comments

In response to the Office Action of July 2, 2004, and supplemental to the Amendment Under 37 C.F.R. § 1.111, filed November 2, 2004, please amend the above-identified patent application as set forth below:

Amendments to the claims begin at page 2 of this document.

Remarks begin at page 12 of this document.